U.S. Markets closed

CinCor Pharma, Inc. (CINC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
29.060.00 (0.00%)
At close: 05:00PM EDT

CinCor Pharma, Inc.

City Point
6th Floor 230 Third Avenue
Waltham, MA 02451
United States
844 531 1834

Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. Marc M. P. de GaridelCEO & Director776.86kN/A1958
Dr. Mason W. Freeman M.D.Chief Medical Officer285.56kN/A1951
Ms. Catherine Pearce DHSc, M.B.A., MBACo-Founder & COON/AN/A1976
Mr. Michael W. Kalb CPAExec. VP, CFO & Principal Accounting OfficerN/AN/A1971
Ms. Ida HatoumSr. VP and Head of People, Talent & CultureN/AN/AN/A
Hema KeshavaCorp. ControllerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. The company was incorporated in 2018 and is based in Waltham, Massachusetts.

Corporate Governance

CinCor Pharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.